(Q38083794)

28 August 2017

Trametinib (GSK1120212) in the treatment of melanoma (English)

1 reference

trametinib dimethyl sulfoxide

28 August 2017

1 reference

ChEBI release 2020-05-28

1 reference

ChEBI release 2020-05-28

April K S Salama

1

1 reference

PubMed ID

23432625

28 August 2017

Kevin B Kim

series ordinal

2

1 reference

PubMed ID

23432625

28 August 2017

language of work or name

English

0 references

publication date

23 February 2013

1 reference

Expert Opinion on Pharmacotherapy

28 August 2017

1 reference

28 August 2017

14

1 reference

28 August 2017

5

1 reference

28 August 2017

619-627

1 reference

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

28 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.770475

Treatment for metastatic malignant melanoma: old drugs and new strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.770475

Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.770475

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.770475

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.770475

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.770475

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.770475

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.770475

Different effects of point mutations within the B-Raf glycine-rich loop in colorectal tumors on mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase and nuclear factor kappaB pathway and cellul

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.770475

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.770475

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.770475

MAP kinase signalling pathways in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.770475

Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.770475

BRAF mutation predicts sensitivity to MEK inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.770475

The primary structure of MEK, a protein kinase that phosphorylates the ERK gene product

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.770475

The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.770475

Distinct sets of genetic alterations in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.770475

Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.770475

Mutations in GNA11 in uveal melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.770475

Improved survival with MEK inhibition in BRAF-mutated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.770475

Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.770475

Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.770475

Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.770475

A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.770475

GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.770475

(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.770475

PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.770475

Identification of a novel inhibitor of mitogen-activated protein kinase kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.770475

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.770475

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.770475

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.770475

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.770475

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.770475

MEK1 mutations confer resistance to MEK and B-RAF inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.770475

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.770475

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.770475

Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.770475

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.770475

Effectiveness of treatments for metastatic uveal melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.770475

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.770475

Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.770475

BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.770475

Taking stock of translational research in melanoma at the 2010 Society for Melanoma Research Congress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.770475

Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.770475

10.1517/14656566.2013.770475

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference

PubMed ID

23432625